摘要
背景/目的:阿尔茨海默症是一种复杂的神经退行性疾病,越来越多的证据表明神经性炎症在阿尔茨海默症的致病机理中的重要性。AD患者的脑部会激活补体,并可能会导致局部的炎症状况。许多研究都观察到了AD患者血清第四补体4的过度表达。这个蛋白质有两种亚型,由两种基因编码:位于HLA系 III 区域的C4A和C4B。这些基因抑制了拷贝数变异(CNVs),这种不同的基因拷贝数会影响C4蛋白水平。我们主要研究这两种基因,通过将AD病人和正常对照组的CNVs分布进行对比,来分析它们在AD致病因素的可能相关性。 方法:我们研究了191例AD患者和300例健康对照。C4A与C4B的拷贝数由定量PCR(qPCR)检测。 结果:得到的结果显示与健康对照组进行对比,C4A和C4B的拷贝数在AD患者体内有统计学意义的上升了。(p<0.001) 结论:AD患者体内C4A和C4B高拷贝数的存在可能解释了AD患者体内检测到的C4蛋白的过度表达,因此,突显了C4A和C4B拷贝数变异在发生AD风险中的作用。
关键词: 阿尔茨海默症,补体系统,C4A
Current Alzheimer Research
Title:Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Volume: 14 Issue: 3
Author(s): Michele Zorzetto, Francesca Datturi, Laura Divizia, Cristiana Pistono, Ilaria Campo, Annalisa De Silvestri, Mariaclara Cuccia and Giovanni Ricevuti.
Affiliation:
关键词: 阿尔茨海默症,补体系统,C4A
摘要: Background/Objectives: Increasing evidence suggests the importance of neuroinflammation in the pathogenesis of Alzheimer’s disease (AD), which is a complex neurodegenerative disorder. Complement activation occurs in the brain of patients with AD and seems to contribute to an important local inflammatory state. Increased expression of the fourth serum complement component 4 (C4) has been observed in AD patients in many studies. This protein has two isoforms, encoded by two genes: C4A and C4B localized to the HLA class III region. These genes exhibit copy number variations (CNVs) and this different gene copy number can influence C4 protein levels. We focalized our attention on these two genes, determining the distribution of CNVs in AD patients, compared with healthy controls, in order to analyse their possible involvement in AD pathogenesis.
Methods: We investigated 191 AD patients and 300 healthy controls. The C4A and C4B copy numbers were assessed by quantitative PCR (qPCR).
Results: The results obtained showed a statistically significant increase in the number of copies for both C4A and C4B in AD patients, compared with healthy controls (p<0,001).
Conclusion: The presence of high C4A and C4B copy numbers in AD patients could explain the increased C4 protein expression observed in AD patients, thus highlighting a possible role for C4A and C4B CNVs in the risk of developing AD.
Export Options
About this article
Cite this article as:
Michele Zorzetto, Francesca Datturi, Laura Divizia, Cristiana Pistono, Ilaria Campo, Annalisa De Silvestri, Mariaclara Cuccia and Giovanni Ricevuti. , Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161013091934
DOI https://dx.doi.org/10.2174/1567205013666161013091934 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins
Current Pharmaceutical Design G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Age-Related Increase in Levels of 5-Hydroxymethylcytosine in Mouse Hippocampus is Prevented by Caloric Restriction
Current Alzheimer Research Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders
Combinatorial Chemistry & High Throughput Screening Critical Issues in Delivery of RNAi Therapeutics In Vivo
Current Pharmaceutical Biotechnology The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure
Current Medicinal Chemistry Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways
Current Molecular Medicine A Peptide Based Pro-Drug Ameliorates Amyloid-β Induced Neuronal Apoptosis in In Vitro SH-SY5Y Cells
Current Alzheimer Research The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine